Long-term effectiveness of isoniazid prophylaxis on TB incidence in a cohort of IDUs

HIV Treatment Bulletin - Vol. 8, No. 6/7, June-July 2007

Jonathan Golub and co-workers from the AIDS Linked to Intravenous Experience (ALIVE), cohort in Baltimore USA assessed long-term effectiveness of an 8-year tuberculin skin testing (TST)/isoniazid (IPT) programme among a cohort of HIV-positive and HIV-negative IDUs.

This cohort includes >2000 IDUs in Baltimore, 35% of whom were HIV-positive at baseline. TST and IPT were offered to all ALIVE participants from 1990 to 1998. TB incidence was measured in 3 periods: pre-purified protein derivative (PPD) era (1988-1990), PPD era (1990-1998), and post-PPD era (1998-2004). Incidence rate ratios compared TB incidences among eras.

The investigators found out of a group of 753 HIV-positive participants, 651 (86%) had a TST ; 103 (16%) had a positive result (>5 mm); 65 (60%) started IPT; and 40 (62%) completed 6 months. Of the1264 HIV-negative participants, 1105 (87%) had a TST; 435 (39%) had a positive result (>10 mm); 246 (56%) started IPT; and 133 (54%) completed 6 months. In total, 32% of those with a positive TST completed 6 months of IPT.

In this study 30 TB cases were diagnosed over 28,750 person-years: IR = 1.04/1000 person-years in HIV-negative; IR = 2.66/1000 person-years among the HIV-positive population. The investigators reported TB incidence in the post-PPD-era for the overall cohort was half that seen in the PPD-era (IRR = 0.44, 95%CI 0.19 to 1.04), but they found no significant difference between eras in the HIV-positive population (2.04 vs 3.14/1000 person-years; IR = 0.64, 95%CI 0.27 to 1.58).

Both overall and amongst the HIV-positive participants, TB incidence among those who never received IPT was greater than those who started IPT; no cases were detected for those who received 6 months of IPT. Among the HIV-positive participants the investigators found body mass index <21 (RH = 3.1, p <0.01) and CD4 <200 (RH = 9.6, p <0.01) to be most predictive of TB. ART use had no association with risk of TB.

The investigators reported that a significant long-term reduction in TB incidence was observed in a cohort of IDU with a high HIV prevalence after an 8-year strategy of TST/IPT, but no change was seen in the HIV-positive subset. They noted that IPT was highly effective for those who completed it, but only 32% of TST-positive patients completed. “Broader use of IPT in HIVIDUs could substantially decrease TB incidence” they wrote.

Ref: Jonathan Golub, J Astemborski, M Ahmed et al. Long-term effectiveness of isoniazid preventive therapy on TB Incidence in a cohort of injection drug users. 14th CROI, 2007. Los Angeles. Abstract 851.

2007-06-10
IB070806-19

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.